Researchers from Molecular Partners AG reported on the preclinical evaluation of MP-0533, a multispecific T-cell engaging DARPin (designed ankyrin repeat protein) targeting CD70, CD123, CD33 and CD3 tumor-associated antigens (TAA) simultaneously.